Skip to Main Content
Newsroom
Get in Touch
LinkedIn
Editas Medicine Linkedin
Research and Pipeline
CRISPR Gene Editing
For Patients
Who We Are
Join Our Team
Investors
Newsroom
Get in Touch
LinkedIn
Purchasing Policy Terms and Conditions
+
-
Editas Newsroom
Jun
7
Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer
Jun
6
Editas Medicine Reports Inducement Grants to New Chief Executive Officer
May
18
Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting